G 207

Drug Profile

G 207

Alternative Names: G207

Latest Information Update: 30 Aug 2010

Price : $50

At a glance

  • Originator Georgetown University Medical Center
  • Developer MediGene Inc
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma

Highest Development Phases

  • Discontinued Glioma

Most Recent Events

  • 17 Jan 2008 G 207 is still in phase I trials for Glioma in USA
  • 13 Jun 2005 Phase-I clinical trials in Glioma in USA (Intratumoural)
  • 09 Sep 2003 No development reported - Phase-II for Basal cell cancer in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top